Nilesh Kumar

Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA.

Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA.

Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden.

TocopheRx, Inc. developed novel therapies for treatment of infertility. The company was founded by Stephen Palmer, Selva Nataraja, and Henry Yu on December 2, 2013 and was headquartered in Gorton, MA.

Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland.

Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA.

Raze Therapeutics, Inc. engages in the discovery and development of oncology therapeutics. It offers a pipeline of one-carbon (1C) metabolism therapeutics across solid and hematologic cancers, including genetically-defined cancers. The company was founded by Vamsi Mootha, Joshua Rabinowitz, David Sabatini, and Adam Friedman on August 8, 2014 and is headquartered in Cambridge, MA.

Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.

Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY.

Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA.

Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA.

Wellington Management Co. LLP (Private Equity) (Wellington Management) is a private equity firm, a subsidiary of Wellington Management Co. LLP founded in 1933. The firm is headquartered in Boston, Massachusetts.

F-Star Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of immune-oncology drugs for antibody therapies. The company was founded in 2006 and is headquartered in Cambridge, the United Kingdom.